Ireland· IE-PA-EU/1/24/1843/002
Ordspono 80 mg Concentrate for solution for infusion
A odronextamab product containing odronextamab, registered in Ireland by Regeneron Ireland Designated Activity Company. The same ATC class is registered in 6 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Odronextamab is registered in 6 of 19 countries.
Countries holding a registration under ATC L01FX34 (odronextamab), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 3 of them publish a price we can compare per daily dose
Odronextamab · ATC L01FX34
6 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Ireland
- Netherlands
The record
At a glance
HPRA (Ireland)- Active substance
- Odronextamab
- Manufacturer
- Regeneron Ireland Designated Activity Company
- Country
- Ireland (IE)
- ATC code
- L01FX34
- ATC class
- Odronextamab
- Defined daily dose
- 12.86 mg, P
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/24/1843/002
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Odronextamab in 8 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumOrdspono 80 mgRegeneron Ireland Designated Activity Company (DAC)
- CzechiaORDSPONORegeneron Ireland Designated Activity Company, Dublin
- FinlandOrdsponoRegeneron Ireland Designated Activity Company (DAC)
- IcelandOrdsponoRegeneron Ireland Designated Activity Company
- PolandOrdsponoRegeneron Ireland Designated Activity Company (DAC)
- SwedenOrdspono 80 mg Koncentrat till infusionsvätska, lösningRegeneron Ireland Designated Activity Company
- SpainORDSPONO 2 MG CONCENTRADO PARA SOLUCION PARA PERFUSIONRegeneron Ireland Designated Activity Company
- NetherlandsOrdspono 2 mg concentraat voor oplossing voor infusieRegeneron Ireland Designated Activity Company
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Ordspono
- Liechtenstein · Ordspono
- Norway · Ordspono
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b6195adc-e94f-46cd-ab8b-451dc7d7177d GET /v1/drugs/b6195adc-e94f-46cd-ab8b-451dc7d7177d?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Concentrate for solution for infusion",
"routes": [
"Intravenous use"
],
"source": "hpra",
"atc_all": [
"L01FX34"
],
"strength": null,
"pa_number": "EU/1/24/1843/002",
"substances": [
"Odronextamab"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": "22/08/2024",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about odronextamab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.